USFDA concludes audit at Jeevan Scientific Technology’s Bioanalytical facility in Hyderabad

24 Jan 2020 Evaluate

United States Food and Drug Administration (USFDA) has concluded audit at Jeevan Scientific Technology’s Bioanalytical facility in Hyderabad. The purpose of this audit was to review the BA/BE studies conducted at facilities. The auditors started the review on January 20, 2020 and completed on January 24, 2020.

The audit concluded with ‘No Observations’. This audit is specifically to access and approve the Bioequivalence studies conducted by the company for Pharmaceutical companies across the globe.

Jeevan Scientific Technology provides a range of clinical research services for healthcare/pharmaceutical industries in India and internationally. Its clinical research services comprise bio-analytical, clinical data management, biostatistics and statistical programming, medical writing, pharmacovigilance, regulatory affairs, quality assurance, and project management services, as well as clinical operation and scientific writing services.

Jeevan Scientific Share Price

53.13 1.97 (3.85%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
TCS 3827.45
Infosys 1411.60
HCL Tech. 1450.00
Wipro 452.85
Tech Mahindra 1193.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.